Our unique size, the competencies of our teams and of our network of external advisers, our financial resources and business model allow us to independently fund and manage each in-licensed product for success.
We provide shared goals and objectives including :
- rapid and successful product development
- maximum return on investment
- product sustainability and viability
- global commercial success
Our main therapeutic areas of interest are oncology, immunology, metabolic disorders and infectious diseases, all severe, chronic medical conditions.
We also have competence in orphan and niche indications within our therapeutic areas.
Products can include both small molecules and exciting biologics such as proteins, peptides and monoclonal antibodies, as well as new chemical entities.
Evaluation & partnering process
We have a systematic, stringent and aggressive but open-minded evaluation process. Out of 1'000 opportunities examined during a calendar year, we typically license-in up to five new molecules. Chosen projects are allocated realistic resources for development.
We aim to have and maintain ten products in clinical development in our portfolio, with about half biologicals and half oncology products. These products should be first-in-class or best-in-class development candidates with positive in vivo results.
Our evaluation teams are interested in investigating any drug development candidate in our main therapeutic areas, especially those that have shown promising results in an animal model, although we are prepared to consider earlier stage candidates. We are also interested in licensing-in development products that can benefit from our formulation and drug delivery capabilities.
If you have a molecule with an interesting therapeutic potential, please use this form.